MedPath

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Phase 2
Completed
Conditions
Asthma
Interventions
Registration Number
NCT01696071
Lead Sponsor
Boehringer Ingelheim
Brief Summary

Determine the 24-hour FEV1-profile of tiotropium solution for inhalation after 4 weeks treatment periods of 5 mcg tiotropium administered once daily in the evening and 2.5 mcg tiotropium administered twice daily (morning and evening). In addition compare the 24 hours pharmacokinetic profile of 5 mcg tiotropium administered once daily and 2.5mcg tiotropium administered twice daily in pharmacokinetic sub-investigation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
98
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Treatment ATiotropium 5 mcg qd2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
Treatment BTiotropium 2.5 mcg bid2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
Primary Outcome Measures
NameTimeMethod
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 - 24h (AUC 0-24) Response.Baseline FEV1 taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes (min) prior to dose to 30 min,1 hour (h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

Mixed Model Repeated Measure (MMRM) results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.

The values recorded at 11 hours 50 minutes and at 23 hours 50 minutes post dosing were assigned to 12 and 24 hours, respectively.

Secondary Outcome Measures
NameTimeMethod
FEV1 AUC0-12h ResponseBaseline FEV1 taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

FEV1 AUC12-24h ResponseBaseline FEV1 taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12 -24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

Forced Vital Capacity (FVC) AUC0-24h ResponseBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.

The values recorded at 11 hours 50 minutes and at 23 hours 50 minutes post dosing were assigned to 12 and 24 hours, respectively.

FVC AUC0-12h ResponseBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

Peak FVC ResponseBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. Peak FVC was defined as the highest FVC reading observed within the 24 hour period following inhalation of the last evening dose of study medication (FVC Peak0-24h).

Trough FVC ResponsesBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. Trough FVC was defined as the FVC value just prior to the last evening dose of study medication.

Peak FEV1 Response.10 minutes (min) prior to dose to 30 min,1 hour (h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks.

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. Peak FEV1 was defined as the highest FEV1 reading observed within the 24 hour period following inhalation of the last evening dose of study medication (FEV1 Peak0-24h). The values recorded at 11 hours 50 minutes and at 23 hours 50 minutes post dosing were assigned to 12 and 24 hours, respectively.

Trough FEV1 (L) Response.10 minutes (min) prior to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. Trough FEV1 was defined as the FEV1 value just prior to the last evening dose of study medication.

FVC AUC12-24h ResponseBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12 -24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.

Peak Expiratory Flow (PEF) AUC0-24h ResponseBaseline taken at visit 2 prior to the first evening dose of randomised study medication. Then, 10 minutes(min) prior to dose to 30min,1hour(h),2h,3h,4h,11h50min,12h30min,13h,14h,15h,16h,18h,20h,22h and 23h,23h50min relative to dose after 4 weeks

MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres per minute.

Trial Locations

Locations (22)

205.441.49003 Boehringer Ingelheim Investigational Site

🇩🇪

Frankfurt, Germany

205.441.49015 Boehringer Ingelheim Investigational Site

🇩🇪

Berlin, Germany

205.441.49014 Boehringer Ingelheim Investigational Site

🇩🇪

Frankfurt, Germany

205.441.49007 Boehringer Ingelheim Investigational Site

🇩🇪

Großhansdorf, Germany

205.441.49005 Boehringer Ingelheim Investigational Site

🇩🇪

Hannover, Germany

205.441.49004 Boehringer Ingelheim Investigational Site

🇩🇪

Leipzig, Germany

205.441.49010 Boehringer Ingelheim Investigational Site

🇩🇪

Lübeck, Germany

205.441.49013 Boehringer Ingelheim Investigational Site

🇩🇪

Mannheim, Germany

205.441.49001 Boehringer Ingelheim Investigational Site

🇩🇪

Neu-Isenburg, Germany

205.441.49002 Boehringer Ingelheim Investigational Site

🇩🇪

Wiesbaden, Germany

205.441.49011 Boehringer Ingelheim Investigational Site

🇩🇪

Wiesloch, Germany

205.441.36003 Boehringer Ingelheim Investigational Site

🇭🇺

Cegled, Hungary

205.441.36002 Boehringer Ingelheim Investigational Site

🇭🇺

Godollo, Hungary

205.441.36004 Boehringer Ingelheim Investigational Site

🇭🇺

Szigetszentmiklos, Hungary

205.441.38601 Boehringer Ingelheim Investigational Site

🇸🇮

Golnik, Slovenia

205.441.43001 Boehringer Ingelheim Investigational Site

🇦🇹

Thalheim bei Wels, Austria

205.441.36005 Boehringer Ingelheim Investigational Site

🇭🇺

Szazhalombatta, Hungary

205.441.43002 Boehringer Ingelheim Investigational Site

🇦🇹

Wels, Austria

205.441.38602 Boehringer Ingelheim Investigational Site

🇸🇮

Kamnik, Slovenia

205.441.43004 Boehringer Ingelheim Investigational Site

🇦🇹

Grieskirchen, Austria

205.441.43003 Boehringer Ingelheim Investigational Site

🇦🇹

Linz, Austria

205.441.36001 Boehringer Ingelheim Investigational Site

🇭🇺

Pecs, Hungary

© Copyright 2025. All Rights Reserved by MedPath